A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read FDA Compliance for Peptide Therapy and BPC 157 Holt Law Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step